Mathematical modeling of prostate cancer progression in response to androgen ablation therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 49, 2011, Pages 19701-19706

  Jain, Harsh Vardhan ^a   Clinton, Steven K ^b   Bhinder, Arvinder ^b   Friedman, Avner ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Castration resistance; Continuous androgen ablation; Intermittent androgen ablation; Rapid antiandrogen cycling

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ANTIANDROGEN THERAPY; ARTICLE; CANCER GROWTH; CASTRATION; CELL PROLIFERATION; CELL TYPE; CLINICAL ARTICLE; EPIGENETICS; EPITHELIUM CELL; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; MALE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION; TREATMENT RESPONSE;

ALGORITHMS; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELLS, CULTURED; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TESTOSTERONE; TREATMENT OUTCOME;

EID: 83755178426     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115750108     Document Type: Article

References (29)

1. Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324:236-245.
2. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118-1126. (Pubitemid 26274606)
3. Miyamoto H, Messing EM, Chang C (2004) Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 61:332-353. (Pubitemid 39571710)
4. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308. (Pubitemid 38501396)
5. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS (1999) Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 140:4509-4515. (Pubitemid 30666115)
6. Agus DB, et al. (1999) Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91:1869-1876.
7. Ferlay J, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592. (Pubitemid 46359643)
8. Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240.
9. Seidenfeld J, et al. (2000) Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 132:566-577. (Pubitemid 30171897)
10. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K (1991) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67:502-508.
11. Balk SP (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-138.
12. de Bono JS, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005.
13. Hussain M, et al. (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from the Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27:2450-2456.
14. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45. (Pubitemid 33741879)
15. Shah S, Small E (2010) Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther 10:89-101.
16. Jackson TL (2004) A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete Continuous Dyn Syst Ser B 4:187-201.
17. Jackson TL (2004) A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 6:697-704.
18. Ideta A, Tanaka G, Takeuchi T, Aihara K (2008) A mathematical model of intermittent androgen suppression for prostate cancer. J Nonlinear Sci 18:593-614.
19. Potter LK, Zager MG, Barton HA (2006) Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats. Am J Physiol Endocrinol Metab 291:E952-E964.
20. Eikenberry SE, Nagy JD, Kuang Y (2010) The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct 5:24-52.
21. Bosch JLHR, Tilling K, Bohnen AM, Bangma CH, Donovan JL (2007) Establishing normal reference ranges for prostate volume change with age in the populationbased Krimpen-study: Prediction of future prostate volume in individual men. Prostate 67:1816-1824. (Pubitemid 350228733)
22. Cher ML, et al. (1996) Genetic alterations in untreated metastases and androgenindependent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102. (Pubitemid 26199756)
23. Richardson TD, Oesterling JE (1997) Age-specific reference ranges for serum prostatespecific antigen. Urol Clin North Am 24:339-351. (Pubitemid 27169259)
24. Young CY, et al. (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51:3748-3752.
25. Brawer MK (1995) How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 45:148-164.
26. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS (1996) Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98:2558-2563. (Pubitemid 26415076)
27. Berges RR, et al. (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480.
28. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45:839-844.
29. Feltquate D, et al. (2006) Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res 12:7414-7421. (Pubitemid 46095416)